keyword
MENU ▼
Read by QxMD icon Read
search

managment tnbc

keyword
https://www.readbyqxmd.com/read/28211614/opportunities-for-improving-triple-negative-breast-cancer-outcomes-results-of-a-population-based-study
#1
Elisabetta Rapiti, Kim Pinaud, Pierre O Chappuis, Valeria Viassolo, Aurélie Ayme, Isabelle Neyroud-Caspar, Massimo Usel, Christine Bouchardy
Triple-negative breast cancer (TNBC) is associated with a poor prognosis. Surgery, radiotherapy, chemotherapy, and referral for genetic counseling are the standard of care. We assessed TNBC prevalence, management, and outcome using data from the population-based Geneva cancer registry. 2591 women had a first invasive stage I-III breast cancer diagnosed between 2003 and 2011. We compared TNBC to other breast cancers (OBC) by χ(2) -test and logistic regression. Kaplan-Meier survival curves, up to 31-12-2014, were compared using log-rank test...
February 17, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28194329/understanding-breast-cancer-the-long-and-winding-road
#2
REVIEW
Kiven Erique Lukong
BACKGROUND: Despite a remarkable increase in the depth of our understanding and management of breast cancer in the past 50 years, the disease is still a major public health problem worldwide and poses significant challenges. The palpability of breast tumors has facilitated diagnosis and documentation since ancient times. The earliest descriptions of breast cancer date back to around 3500 BCE. For centuries to follow, theories by Hippocrates (460 BCE) and Galen (200 CE), attributing the cause of breast cancer to an "excess of black bile" and treatment options including the use of opium and castor oil, prevailed...
June 2017: BBA Clinical
https://www.readbyqxmd.com/read/28135048/identification-of-recurrent-brca1-mutation-and-its-clinical-relevance-in-chinese-triple-negative-breast-cancer-cohort
#3
Xiaoran Liu, Huiping Li, Bin Shao, Jianmin Wu, Weiyao Kong, Guohong Song, Hanfang Jiang, Jing Wang, Fengling Wan
Triple-negative breast cancer (TNBC) accounts for 15-20% of all newly diagnosed breast cancers, and is enriched for germline mutation of BRCA. In Asian patients diagnosed with breast cancer, 268 deleterious mutations of BRCA1 and 242 of BRCA2 have been identified so far, including a reported BRCA1 frameshift mutation (rs80350973), apparently found only in Asian people, with a low prevalence of 0.3-1.7% in different breast cancer cohorts. Here, we reported the high prevalence (7.2%) of rs80350973 among 125 Chinese patients with TNBC, which implies its mutational predilection for certain breast cancer subtypes...
January 30, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28108861/in-vivo-magnetic-resonance-imaging-investigating-the-development-of-experimental-brain-metastases-due-to-triple-negative-breast-cancer
#4
Amanda M Hamilton, Paula J Foster
Triple negative breast cancer (TNBC), when associated with poor outcome, is aggressive in nature with a high incidence of brain metastasis and the shortest median overall patient survival after brain metastasis development compared to all other breast cancer subtypes. As therapies that control primary cancer and extracranial metastatic sites improve, the incidence of brain metastases is increasing and the management of patients with breast cancer brain metastases continues to be a significant clinical challenge...
January 21, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28006062/association-between-benign-breast-disease-in-african-american-and-white-american-women-and-subsequent-triple-negative-breast-cancer
#5
Lisa A Newman, Azadeh Stark, Dhanajay Chitale, Margaret Pepe, Gary Longton, Maria J Worsham, S David Nathanson, Patricia Miller, Jessica M Bensenhaver, Erica Proctor, Monique Swain, Christos Patriotis, Paul F Engstrom
Importance: Compared with white American (WA) women, African American (AA) women have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC. Objective: To determine whether AA identity remains associated with TNBC for women with a prior diagnosis of BBD...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27959276/identification-and-targeting-of-micrornas-modulating-acquired-chemotherapy-resistance-in-triple-negative-breast-cancer-tnbc-a-better-strategy-to-combat-chemoresistance
#6
Samayita Das
Triple negative breast cancer (TNBC) is a heterogeneous form of malignant disease. Due to lack of proper therapeutic target treatment options are restricted and relies primarily on chemotherapeutic modality for treatment of patients. Despite significant early regression of the disease in response to chemotherapy, complete cure is not assured with development of resistant tumors which is difficult to manage clinically. In the last decades, the regulation and contribution of microRNAs in tumorigenesis including breast cancers have been well-documented...
November 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/27882217/multiple-effects-of-xihuang-pill-aqueous-extract-on-the-hs578t-triple-negative-breast-cancer-cell-line
#7
Wenxian Zheng, Shuyan Han, Shantong Jiang, Lina Pang, Xiaohong Li, Xijuan Liu, Minhua Cao, Pingping Li
The management of triple-negative breast cancer (TNBC) is challenging due to the aggressive behavior, lack of therapeutic options and relatively poor prognosis. Xihuang pill (XHP) is a well-known Traditional Chinese Medicine with anticancer activity. The aim of the present study was to investigate whether the aqueous extract of XHP (AEXHP) has anti-proliferative activity against the Hs578T TNBC cell line, and to elucidate its molecular mechanisms of action. First, an MTT assay was used to evaluate the anti-proliferative activity of AEXHP on the Hs578T cell line; furthermore, the cell cycle distribution, mitochondrial membrane potential and apoptotic rate were determined by flow cytometry, and western blot analysis was used to assess the expression of apoptosis and cell cycle regulatory proteins to investigate the mechanisms of action...
November 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27856201/daily-practice-management-of-pt1a-b-pn0-breast-carcinoma-a-prospective-french-odissee-cohort-study
#8
Florence Dalenc, Frédérique Penault-Llorca, Monique Cohen, Gilles Houvenaeghel, Jean-Marc Piat, Philippe Liegeois, Laurent Puyuelo, Jean-Philippe Suchaud, Mohammed Zouai, Magali Lacroix-Triki, Nina Radosevic-Robin, Chahinez Benkanoun, Hanane Attar-Rabia, Marie-Pierre Chauvet, Joseph Gligorov, Yazid Belkacemi
BACKGROUND: Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery...
August 31, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27817751/novel-insight-into-triple-negative-breast-cancers-the-emerging-role-of-angiogenesis-and-antiangiogenic-therapy
#9
Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, Ciprian Tomuleasa, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours characterised by lack of expression of oestrogen-, progesterone- and human epidermal growth factor receptors. TNBC, which represents approximately 15% of all mammary tumours, has a poor prognosis because of an aggressive behaviour and the lack of specific treatment. Accordingly, TNBC has become a major focus of research into breast cancer and is now classified into several molecular subtypes, each with a different prognosis. Pathological angiogenesis occurs at a late stage in the proliferation of TNBC and is associated with invasion and metastasis; there is an association with metabolic syndrome...
November 7, 2016: Expert Reviews in Molecular Medicine
https://www.readbyqxmd.com/read/27816751/growth-hormone-releasing-hormone-induced-transactivation-of-epidermal-growth-factor-receptor-in-human-triple-negative-breast-cancer-cells
#10
Eva Vacas, Laura Muñoz-Moreno, Pedro L Valenzuela, Juan C Prieto, Andrew V Schally, María J Carmena, Ana M Bajo
Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells...
December 2016: Peptides
https://www.readbyqxmd.com/read/27796714/up-regulation-of-cathepsin-s-expression-by-hsp90-and-5-ht7-receptor-dependent-serotonin-signaling-correlates-with-triple-negativity-of-human-breast-cancer
#11
Jaya Gautam, Young Kyung Bae, Jung-Ae Kim
PURPOSE: Cathepsin S (CTSS) is expressed in a variety of cancers and stimulates tumor progression. However, the regulatory mechanism and role of CTSS in breast cancer progression are poorly understood. The aim of this study was to examine the relationships between CTSS expression and breast cancer grade and stage, and the signaling molecules involved in CTSS expression. METHODS: Immunohistochemical staining was performed in tissue microarray sections of 1451 human invasive breast cancer samples to determine epithelial (E-CTSS) and stromal CTSS (S-CTSS) expression...
October 27, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27770782/triple-negative-breast-cancer-in-north-of-morocco-clinicopathologic-and-prognostic-features
#12
Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita
BACKGROUND: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco. METHODS: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015...
October 22, 2016: BMC Women's Health
https://www.readbyqxmd.com/read/27765921/triple-negative-breast-cancer-is-there-a-treatment-on-the-horizon
#13
REVIEW
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng
Triple-negative breast cancer (TNBC), which accounts for 15-20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/27721875/histomorphological-factors-predicting-the-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#14
Yoon Yang Jung, Chang Lim Hyun, Min-Sun Jin, In Ae Park, Yul Ri Chung, Bobae Shim, Kyu Ho Lee, Han Suk Ryu
PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled...
September 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/27665540/nab-paclitaxel-for-the-treatment-of-triple-negative-breast-cancer-rationale-clinical-data-and-future-perspectives
#15
REVIEW
Francesco Schettini, Mario Giuliano, Sabino De Placido, Grazia Arpino
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far been disappointing; chemotherapy, in particular with anthracycline and taxanes, remains the backbone medical management for both early and metastatic TNBC. Nab-paclitaxel is a solvent-free, albumin-bound, nanoparticle formulation of paclitaxel and represents a novel formulation of an established, effective chemotherapeutic agent...
November 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27494850/the-3-utr-signature-defines-a-highly-metastatic-subgroup-of-triple-negative-breast-cancer
#16
Lei Wang, Xin Hu, Peng Wang, Zhi-Ming Shao
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3'UTR patterns to improve postoperative risk stratification. We collected 327 publicly available microarrays and generated the 3'UTR landscape based on expression ratios of alternative 3'UTR. After initial feature filtering, we built a 17-3'UTR-based classifier using an elastic net model. Time-dependent ROC comparisons and Kaplan-Meier analyses confirmed an outstanding discriminating power of our prognostic model for TNBC patients...
September 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27462789/il-17e-synergizes-with-egf-and-confers-in-vitro-resistance-to-egfr-targeted-therapies-in-tnbc-cells
#17
Yacine Merrouche, Joseph Fabre, Herve Cure, Christian Garbar, Camille Fuselier, Jeremy Bastid, Frank Antonicelli, Reem Al-Daccak, Armand Bensussan, Jerome Giustiniani
Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors. Resistance to anti-EGFR therapeutic agents is often associated with sustained kinase phosphorylation, which promotes EGFR activation and translocation to the nucleus and prevents these agents from acting on their targets. The mechanisms underlying this resistance have not been fully elucidated...
August 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27461138/novel-targets-for-paclitaxel-nano-formulations-hopes-and-hypes-in-triple-negative-breast-cancer
#18
REVIEW
Anita K Bakrania, Bhavesh C Variya, Snehal S Patel
Triple negative breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned. The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor. Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its solubility is often a challenge to scientists in achieving success...
September 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27456662/triple-negative-breast-cancer-a-tale-of-two-decades
#19
Arwa Mohammed Ali, Jawaher Ali Ansari, Nashwa Mohammed AbdelAziz, Waleed Aabozeed, Ahmed Warith, Khalid Alsaleh, Jean-Marc Nabholtz
Triple negative breast cancer (TNBC) is a heterogeneous disease entity constituting about 15% of breast cancer cases worldwide. TNBC is associated with poor prognosis and lack of sustained response to conventional chemotherapeutic agents. Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroup...
July 25, 2016: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/27401886/biology-and-management-of-patients-with-triple-negative-breast-cancer
#20
REVIEW
Priyanka Sharma
UNLABELLED: : Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared with other breast cancer subtypes. Because of the lack of approved targeted therapy, at present chemotherapy remains the mainstay of treatment for early and advanced disease. TNBC is enriched for germline BRCA mutation, providing a foundation for the use of this as a biomarker to identify patients suitable for treatment with DNA-damaging agents...
September 2016: Oncologist
keyword
keyword
55830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"